New hope for preemies: study aims to tame dangerous inflammation
NCT ID NCT07254000
First seen Jan 07, 2026 · Last updated May 20, 2026 · Updated 20 times
Summary
This study tests the drug anakinra in very premature infants (born between 24 and 29 weeks) to find the safest and most effective dose and way to give it (through a vein or under the skin). The goal is to control harmful inflammation that can lead to serious complications. About 24 babies will take part, and researchers will monitor how the drug moves through their bodies and look for early signs of benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Monash Children's Hospital
RECRUITINGClayton, Victoria, 3168, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Starship Children's Hospital
NOT_YET_RECRUITINGGrafton, Auckland, 1023, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.